Latest news about Choksi Laboratories
Choksi Laboratories receives 4 USFDA observations at Indore facility
Choksi Laboratories
195.00
-6.45(-3.20%)
Company Performance:
View Company Insights1D-3.20%
1M+50.06%
6M+80.72%
1Y-6.02%
5Y+980.33%
More news about Choksi Laboratories
04Aug 26
Choksi Laboratories appoints Ankit Consultancy as new RTA effective Aug 3
Choksi Laboratories Limited has switched its Registrar and Share Transfer Agent from MUFG Intime India Private Limited to Ankit Consultancy Private Limited, effective August 03, 2026. The decision was based on service evaluation and technological capabilities. The company published notices in Free Press Journal and Choutha Sansar on August 04, 2026, ensuring regulatory compliance under SEBI LODR Regulations.
26May 26
Choksi Labs FY26 net profit rises 29% to ₹196.43 lakh
Choksi Laboratories Limited reported a 29% increase in net profit to ₹196.43 lakh for FY26, with revenue growing to ₹4621.93 lakh. The Board approved the results on May 25, 2026.
18May 26
Choksi Labs Appoints Mrs. Stela Choksi as CFO
Choksi Laboratories Limited has appointed Mrs. Stela Choksi as its Chief Financial Officer effective May 18, 2026. The board approved the appointment on the recommendation of the Audit and Nomination & Remuneration Committee. Mrs. Stela Choksi is a promoter member with diversified experience in finance and administration.
18May 26
Choksi Laboratories CFO Resigns Effective May 18
Choksi Laboratories announced the resignation of Chief Financial Officer Mr. Vyangesh Choksi, effective May 18, 2026. The resignation, tendered on May 5, 2026, was approved by the board to allow him to focus on new projects. He will continue to serve as the Whole Time Director of the company.
16May 26
Choksi Laboratories Schedules Board Meeting on May 25, 2026 to Approve Q4 and Full-Year FY26 Audited Results
Choksi Laboratories has scheduled its 02/2026-27 Board of Directors meeting for May 25, 2026, at 02:30 P.M. at its registered office in Indore, to consider and approve standalone audited financial results for Q4 and the year ended March 31, 2026. The intimation was filed pursuant to Regulation 29(1) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The trading window, closed since April 1, 2026, will reopen 48 hours after the declaration of the audited results. The filing was submitted by Company Secretary and Compliance Officer Prakhar Dubey on May 16, 2026.
28Apr 26
Choksi Laboratories Completes Postal Ballot with 99.86% Approval for Independent Director Appointment
Choksi Laboratories Limited successfully completed its postal ballot voting process on April 26, 2026, with shareholders approving the appointment of Mr. Ritik Pavecha as Non-Executive Independent Director with 99.86% votes in favor. The remote e-voting conducted through CDSL platform from March 28 to April 26, 2026, saw 20.87% voter turnout with 1453636 votes polled, of which 1451635 supported the resolution and only 2001 opposed. CS Surabhi Agrawal served as scrutinizer, confirming compliance with Companies Act, 2013 and SEBI regulations.
15Apr 26
Choksi Laboratories Confirms Non-Applicability of SEBI Debt Securities Framework for FY26
Choksi Laboratories Limited has confirmed to BSE that it does not qualify as a 'Large Corporate' under SEBI's debt securities framework, exempting it from filing Annual Disclosure requirements for FY26. The confirmation was made pursuant to relevant SEBI circulars and BSE notices governing fund raising through debt securities by large entities.
07Apr 26
Choksi Laboratories Submits Q4FY26 Compliance Certificate Under SEBI Regulation 74(5)
Choksi Laboratories Limited submitted its Q4FY26 compliance certificate under SEBI Regulation 74(5) to BSE Limited on 07-04-2026. The certificate, issued by registrar MUFG Intime India Private Limited, confirms proper handling of securities dematerialisation processes during the quarter ended 31st March 2026. The submission demonstrates the company's adherence to regulatory requirements for depository participant processes and securities handling.
27Mar 26
Choksi Laboratories Publishes Postal Ballot Notice for Director Appointment
Choksi Laboratories Limited has completed newspaper publication requirements for its postal ballot notice regarding the appointment of Mr. Ritik Pavecha as Non-Executive Independent Director. The company published confirmation in Free Press Journal and Choutha Sansar on March 27, 2026, with e-voting scheduled from March 28 to April 26, 2026.
09Feb 26
Choksi Laboratories Publishes Q3FY26 Results in Newspapers, Completes Regulatory Filing
Choksi Laboratories has completed the mandatory newspaper publication of its Q3FY26 financial results in Free Press Journal and Choutha Sansar on February 8, 2026, following SEBI regulatory requirements. The company demonstrated strong financial performance with revenue growth of 4.24% and significant net profit increase of 193.29%, while also implementing board leadership changes with the appointment of Mr. Ritik Pavecha as Additional Non-Executive Independent Director.
07Feb 26
Choksi Laboratories Reconstitutes Board Committees Following Director Changes
Choksi Laboratories Limited reconstituted its Audit Committee, Nomination and Remuneration Committee, and Stakeholders' Relationship Committee on February 07, 2026. The changes followed Mrs. Meenaxi Patidar's resignation as Non-Executive Independent Director on January 09, 2026, and the subsequent appointment of Mr. Ritik Pavecha as additional Non-Executive Independent Director. All committees now comprise independent directors in compliance with SEBI listing regulations and Companies Act requirements.
10Jan 26
Choksi Laboratories Independent Director Mrs. Meenaxi Patidar Resigns Due to Personal Commitments
Mrs. Meenaxi Patidar resigned as Non-Executive Independent Director of Choksi Laboratories Limited effective January 09, 2026, due to preoccupation and personal commitments. Her departure also resulted in her ceasing roles as Audit Committee Member and Chairperson of the Nomination & Remuneration Committee. The company has completed all required regulatory disclosures under SEBI regulations, with Mrs. Patidar confirming no other material reasons for her resignation.
13Aug 25
Choksi Laboratories Reappoints Vyangesh Choksi as Whole Time Director for Five-Year Term
Choksi Laboratories Limited has announced the reappointment of Vyangesh Choksi as Whole Time Director for a five-year term from September 1, 2025, to August 31, 2030, subject to shareholder approval. The decision was made during a board meeting on August 13, 2025. The company also approved financial results, set the date for the 32nd AGM, and made auditor appointments. Vyangesh Choksi is part of the promoter family, with other family members holding key positions in the company.
Industry Peers
Dr. Lal Path Labs
Vijaya Diagnostic Centre
Metropolis Healthcare
Thyrocare Technologies
Nephrocare Health Services
Krsnaa Diagnostics
Suraksha Diagnostic
3B BlackBio DX
One Global Service Provider
Health X Platform
1,896.90
(-1.44%)
1,558.90
(+3.51%)
597.45
(+1.90%)
555.80
(-0.62%)
743.35
(+1.12%)
541.15
(+0.39%)
335.10
(+1.87%)
1,319.30
(+2.21%)
538.75
(+1.56%)
300.00
(0.0%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
